Online Database of Chemicals from Around the World
Search |  Submit |  中文
Home >> Chemical Listing >> H >> (3aS,4S,6aR)-Hexahydro-N-(17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl)-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide

(3aS,4S,6aR)-Hexahydro-N-(17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl)-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
[CAS# 906099-89-6]

List of Suppliers
Hangzhou Molcore Biopharmatech Co., Ltd. China Inquire  
+86 (571) 8102-5280
sales@molcore.com
QQ chat
Chemical manufacturer since 2010
chemBlink standard supplier since 2017
Complete supplier list of (3aS,4S,6aR)-Hexahydro-N-(17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl)-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
Identification
Classification Organic raw materials >> Heterocyclic compound >> Imidazoles
Name (3aS,4S,6aR)-Hexahydro-N-(17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl)-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
Molecular Structure CAS # 906099-89-6, (3aS,4S,6aR)-Hexahydro-N-(17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl)-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
Molecular Formula C22H41N3O8S
Molecular Weight 507.64
CAS Registry Number 906099-89-6
Properties
Solubility Slightly soluble (2.6 g/L) (25 ºC), Calc.*
Density 1.176±0.06 g/cm3 (20 ºC 760 Torr), Calc.*
* Calculated using Advanced Chemistry Development (ACD/Labs) Software V11.02 (©1994-2013 ACD/Labs)
Safety Data
SDS Available
Market Analysis Reports
List of Reports Available for (3aS,4S,6aR)-Hexahydro-N-(17-hydroxy-3,6,9,12,15-pentaoxaheptadec-1-yl)-2-oxo-1H-thieno[3,4-d]imidazole-4-pentanamide
Related Products
Hexahydro-4-(hydroxymethyl)-1,1-dimethyl-4-phenyl-1H-azepinium bromide  (4R,12aS)-3,4,6,8,12,12a-Hexahydro-7-hydroxy-4-methyl-6,8-dioxo-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxylic acid  (6aS,7R,13S,14R,16R)-6,6a,7,13,14,16-Hexahydro-16-(hydroxymethyl)-9-methoxy-8-(methoxymethoxy)-4,10,17-trimethyl-5-(2-propen-1-yloxy)-7,13-imino-12H-1,3-dioxolo[7,8]isoquino[3,2-b][3]benzazocine-14-carbonitrile  (2E,4E)-N-[(2S,5S)-1,2,3,4,5,6-Hexahydro-5-(hydroxymethyl)-1-methyl-2-(1-methylethyl)-3-oxo-1,4-benzodiazocin-8-yl]-5-[4-(trifluoromethyl)phenyl]-2,4-pentadienamide  [3aR-(3aalpha,4alpha,5beta,6aalpha)]-Hexahydro-4-(hydroxymethyl)-5-(phenylmethoxy)-2H-cyclopenta[b]furan-2-one  (1R,2R,3S,6S,7S,7aR)-Hexahydro-3-(hydroxymethyl)-1H-pyrrolizine-1,2,6,7-tetrol  (1R,2R,3R,7R,7aR)-Hexahydro-3-(hydroxymethyl)-1H-pyrrolizine-1,2,7-triol  Hexahydro-3-(hydroxymethyl)-1H-pyrrolizine-1,2,7-triol  (1R,2R,3aS,9aS)-2,3,3a,4,9,9a-Hexahydro-1-[(3S)-3-hydroxyoctyl]-1H-benz[f]indene-2,5-diol  1,2,5,6,8,9-Hexahydro-4-hydroxy-2-oxo-7H-pyrido[2,3-d]azepine-7-carboxylic acid tert-butyl ester  2,3,4,6,7,8-Hexahydro-4-(3-hydroxyphenyl)-7,7-dimethyl-2-thioxo-5(1H)-quinazolinone  Hexahydro-3-(3-hydroxyphenyl)-1-methyl-2H-azepin-2-one  (6S,9aS)-Hexahydro-6-[(4-hydroxyphenyl)methyl]-8-(1-naphthalenylmethyl)-4,7-dioxo-N-(phenylmethyl)-2H-pyrazino[1,2-a]pyrimidine-1(6H)-carboxamide  Hexahydro-2-(3-hydroxytricyclo[3.3.1.13,7]dec-1-yl)-1-iminopyrrolo[1,2-a]pyrazin-4(1H)-one  (3aR,4R,5R,6aS)-Hexahydro-4-[(1E,3R)-3-hydroxy-4-[3-(trifluoromethyl)phenoxy]-1-buten-1-yl]-2H-cyclopenta[b]furan-2,5-diol  2,3,5,6,7,8-Hexahydroimidazo[2,1-b][1,3]thiazepine  (S)-Hexahydroimidazo[1,5-a]pyrazin-3(2H)-one  (8aR)-Hexahydroimidazo[1,5-a]pyrazin-3(2H)-one  N-[[(1,2,3,5,6,7-Hexahydro-s-indacen-4-yl)amino]carbonyl]-4-(1-hydroxy-1-methylethyl)-2-furansulfonamide monosodium salt  Hexahydroindolizin-8-one